2-Substituted Indazoles Inhibit IRAK4 for Immune Overreactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proliferative, autoimmune, metabolic, and inflammatory diseases, such as rheumatoid arthritis and endometriosis, often fail to adequately address the underlying immune system overreactivity, leading to insufficient therapeutic outcomes.
Innovation Solution
Development of 2-substituted indazoles that inhibit interleukin-1 receptor-associated kinase 4 (IRAK4), a key enzyme in the immune system's signaling pathways, to reduce inflammation and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory and autoimmune diseases are used, then existing therapeutic options are available, but they fail to adequately address immune system overreactivity leading to insufficient therapeutic outcomes
Solution Approach 1:
The patent changes the therapeutic parameter by introducing a novel chemical compound (2-substituted indazole derivative) with specific molecular structure modifications. This new compound demonstrates improved therapeutic efficacy by effectively inhibiting IRAK4 kinase activity, thereby adequately addressing immune system overreactivity that current treatments fail to control
Solution Approach 2:
The patent introduces an intermediary substance (2-substituted indazole derivative) that mediates the therapeutic effect by specifically binding to and inhibiting IRAK4 kinase. This intermediary compound acts as a bridge between the treatment need and the biological target, providing the missing link in current therapies that cannot adequately suppress pathological immune responses
2Reliability
If new 2-substituted indazoles are developed to inhibit IRAK4, then therapeutic effectiveness against immune-mediated diseases is improved, but the complexity of drug development and production increases
Solution Approach 1:
The patent segments the complex drug development process by focusing on a specific chemical scaffold (indazole core structure) and systematically modifying it with different substituents at position 2. This segmentation approach allows researchers to methodically optimize the compound's therapeutic effectiveness against IRAK4 while managing development complexity through structured chemical series exploration
3Object-affected harmful factors
If 2-substituted indazoles are used to inhibit IRAK4 signaling, then inflammation and immune response are reduced, but the complexity of the synthesis process increases
Solution Approach 1:
The patent applies preliminary action by pre-synthesizing and characterizing a series of 2-substituted indazole derivatives before clinical evaluation. The synthesis methodology is developed and optimized in advance, with detailed procedures established for producing the active compound and its variants, thereby reducing manufacturing complexity during later production and clinical stages
Data Source
AI summary
The invention relates to new substituted indazoles, to methods for the production of same, to the use of same alone or in combinations to treat and/or prevent diseases, and to the use of same to produce drugs for treating and/or preventing diseases, in particular for treating and/or preventing endometriosis and endometriosis-associated pain and other symptoms associated with endometriosis such as dysmenorrhea, dyspareunia, dysuria, and dyschezia, lymphomas, rheumatoid arthritis, spondyloarthritides (in particular psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver diseases, insulin resistance, tumor diseases, and psoriasis.